Vaccitech collaborators at NIH’s Vaccine Research Center demonstrate that IV administration of SNAPvax in animal models activates two key pathways leading to improved T cell mediated tumor killing in a paradigm referred to as “VAX-INNATE”
VAX-INNATE: Vaccine induced cytotoxic T cells + Innate immune activation and reversal of suppressive tumor microenvironment (TME)
IND submission for SNAPvax candidate for HPV+ cancers (VTP-1100) aiming to leverage VAX-INNATE paradigm planned for first half of 2023
https://finance.yahoo.com/news/publication-cell-shows-vaccitech-snapvax-110000909.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.